Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 1;17(12):5081-5086.
doi: 10.22034/APJCP.2016.17.12.5081.

Clinico-Pathologic Subtypes of Breast Cancer Primary Tumors Are Related to Prognosis after Recurrence

Cesar Sánchez  1 , Mauricio Camus, Lidia Medina, David Oddo, Rocío Artigas, Alejandra Pérez Sepúlveda, Francisco Domínguez, Dravna Razmilic, María Elena Navarro, Hector Galindo, Francisco Acevedo
Affiliations

Clinico-Pathologic Subtypes of Breast Cancer Primary Tumors Are Related to Prognosis after Recurrence

Cesar Sánchez et al. Asian Pac J Cancer Prev. .

Abstract

Background: Pathological factors, based mainly on immunohistochemistry (IHC) and histological differentiation, are mostly used to differentiate breast cancer (BC) subtypes. Our present aim was to describe the characteristics and survival of a relapsing BC patient cohort based on clinico-pathologic subtypes determined for the primary tumors. Methods: We used a clinico- pathological definition of BC subtypes based on histological grade (HG), estrogen receptor (ER), progesterone receptor (PgR),and epidermal growth factor receptor type 2 (HER2) expression assessed by IHC. We determined variables associated with loco-regional recurrence (LRR), second primaries (SP), systemic recurrence (SR) and post-recurrence survival (PRS). Results: Out of 1,702 patients, 240 (14%) had an event defined as recurrence. Those with recurrent disease were significantly younger than those without,and were initially diagnosed at more advanced stages, with larger tumors, greater lymph nodal involvement and higher HG. With a median follow up of 61 months (1-250), 4.6% of patients without recurrence and 56.6% of patients with an event defined as recurrence had died. The median PRS for the LRR group was 77 months; 75 months for those who developed a SP and 22 months for patients with an SR (p <0.0001). In SR cases, the median PRS was shorter for ER- tumors than for ER+ tumors (15 vs. 26 months, respectively; p = 0.0019, HR 0.44; CI: 0.25-0.44). Conclusions: Subtype, defined through classic histopathologic parameters determined for primary tumors, was found to eb related to type of recurrence and also to prognosis after relapse.

Keywords: Breast cancer; subtypes; prognostic; recurrence.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall Survival in 1,702 Patients with Breast Cancer, Based on Presence of Recurrence
Figure 2
Figure 2
Time to Recurrence in 240 Breast Cancer Patients, Based on ER Expression on the Primary Tumor
Figure 3
Figure 3
Overall Survival According to Type of Recurrence in 240 Patients with Breast Cancer
Figure 4
Figure 4
Post-Relapse Survival in 240 Patients with Breast Cancer Based on Type of Recurrence
Figure 5
Figure 5
Post-Relapse Survival in 156 Breast Cancer Patients with Systemic Recurrence Based on ER Expression on the Primary Tumor
See this image and copyright information in PMC

References

    1. Acevedo F, Camus M, Sanchez C. Breast Cancer at Extreme Ages - a Comparative Analysis in Chile. Asian Pac J Cancer Prev. 2015;16:1455–61. - PubMed
    1. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Ann Oncol. 2014;25:1871–88. - PMC - PubMed
    1. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273–8. - PubMed
    1. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31:2783–90. - PubMed
    1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4. - PubMed